Kalytera Announces Binding Agreement to Acquire Salzman Group
Hit enter to search or ESC to close
Kalytera Therapeutics, Inc.
  • Investors
    • Investor Overview
    • Press Releases
    • Company Information
    • SEDAR Filings
    • SEC Filings
    • Stock Information
    • Corporate Governance
  • Contact
  • Investors
    • Investor Overview
    • Press Releases
    • Company Information
    • SEDAR Filings
    • SEC Filings
    • Stock Information
    • Corporate Governance
  • Contact
Media Mentions

CBD-based drug for juvenile epilepsy receives FDA approval [BNN]

By Kalytera June 27, 2018 No Comments

CBD-based drug for juvenile epilepsy receives FDA approval [BNN]

https://www.bnnbloomberg.ca/cbd-based-drug-for-juvenile-epilepsy-receives-fda-approval-1.1098333
Get Email Alerts Subscribe

New Website Coming Soon


© 2020 Kalytera Therapeutics, Inc.

Kalytera Announces Binding Agreement to Acquire Salzman Group
  • Investors
    • Investor Overview
    • Press Releases
    • Company Information
    • SEDAR Filings
    • SEC Filings
    • Stock Information
    • Corporate Governance
  • Contact

© 2016 Kalytera Therapeutics, Inc.